Clinical trials remain the costliest and slowest stage of drug development, with average costs exceeding USD 2 billion per approved drug and timelines often surpassing a decade. Recruitment inefficiencies, high dropout rates, and limited diagnostic integration exacerbate this burden. While decentralized clinical trials (DCTs) promise to reduce patient burden and broaden access, most remain fragmented, with wearables, apps, and telemedicine solutions operating in silos.
Sonali Mallick (Tue,) studied this question.